- The firm also saw another chemotherapy treatment approved by the FDA.
AstraZeneca revealed that the US Food and Drug Administration approved its lung cancer drug along with other chemotherapy treatments.
In a statement, Britain’s largest pharmaceutical group said Imfinzi, in combination with carboplatin and paclitaxel, had been approved, followed by Imfinzi alone.
The FTSE 100-listed company added that this was for adults suffering from “advanced or recurrent primary endometrial cancer that has poor mismatch repair” (dMMR).
AstraZeneca revealed that the US Food and Drug Administration (FDA) approved its lung cancer drug along with other chemotherapy treatments.
The approval came after a trial showed the drug could reduce “the risk of disease progression or death by 58 percent in patients with dMMR endometrial cancer compared to chemotherapy alone.”
Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit, said: “There have been limited advances in the treatment of endometrial cancer in recent decades, and continued innovation is critical as the burden of this cancer is expected to increase. grow in the future.
“Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with repair-deficient disease.”
In the US, endometrial cancer is the fourth most common cancer in women, with more than 66,000 patients diagnosed and almost 12,000 deaths in 2022.
The news comes after the Cambridge-based group revealed in April that Imfinzi showed promise in treating highly aggressive small cell lung cancer.
AstraZeneca said the trial demonstrated a “statistically and clinically significant improvement” in patient survival.
In 2022, just under 2.5 million cases of lung cancer will be diagnosed worldwide.
In May, AstraZeneca said it was targeting $80 billion in annual revenue by 2030, supported by the launch of 20 new drugs.
Britain’s largest pharmaceutical company achieved revenue of $45.8 billion last year, in line with a target set ten years ago, largely thanks to growing demand for its cancer and diabetes treatments.
It now wants to increase annual revenue by a further 75 percent by the beginning of the next decade through continued sales growth from its oncology, biopharmaceuticals and rare diseases portfolio.
AstraZeneca Stock They were down 0.26 per cent at 12,478 pence in Monday morning trading.